In contrast, CDK19 RNA expression was relatively uniform among different cancers, with a prominent elevation in prostate cancers, where CDK19 has been already identified as a marker of carcinogenesis and tumor progression [8]. This evidence concerns the gene CDK19 and neoplasm.